Joseph R. Osborne, M.D, Ph.D.

Founder, Rad Health Equity
Chief of Molecular Imaging & Therapeutics | Physician-Scientist | Innovator in Cancer Diagnostics & Theranostics | Advocate for Health Equity

Joseph R. Osborne, M.D., Ph.D. is a distinguished expert in molecular imaging and radiology, currently serving as Chief of the Molecular Imaging & Therapeutics Service and Professor of Radiology at Weill Cornell Medical College. With an educational foundation that includes a Ph.D. in Cellular and Molecular Biophysics and an M.D. from Columbia University, Osborne has cultivated a profound impact on cancer imaging and therapy.

His research career began under the mentorship of Nobel Laureate Richard Axel, where he developed a strong focus on molecular imaging probes and theranostics, specifically prostate-specific membrane antigen (PSMA) imaging, used in the diagnosis and treatment of prostate cancer.

Dr. Osborne has held various key leadership roles, including his time at Memorial Sloan Kettering Cancer Center as Associate Vice Chairman of Research in Radiology and the Director of Molecular Imaging and Therapy Residency/Fellowship programs. His leadership extends to promoting health equity in radiology, exemplified by his role as Director of the Rad Health Equity Laboratory, where his research addresses both the development of cost-effective diagnostics and addressing healthcare disparities in imaging.

Dr. Osborne’s extensive publication record includes over 80 peer-reviewed papers, contributing significantly to advances in prostate cancer imaging, personalized medicine, and the role of genomic markers in radiological practices. He has led groundbreaking clinical trials focused on novel theranostic approaches to cancer treatment and imaging, which have opened new pathways for integrating diagnostics and therapy in oncology.

His research initiatives have received substantial funding from prominent institutions, including the National Institutes of Health (NIH) and the Department of Defense, further cementing his position as a leading figure in nuclear medicine and molecular imaging.

In addition to his academic and research accomplishments, Osborne has been actively involved in national committees such as the American Thyroid Association’s task force and the FDA’s Medical Imaging Drugs Advisory Committee, contributing to policy shaping and the advancement of diagnostic radiopharmaceuticals.

Dr. Osborne’s career reflects a commitment to innovation, interdisciplinary collaboration, and the pursuit of equity in healthcare, particularly in access to advanced imaging technologies .

Recommended